Epitope Editing Protects Hematopoietic Cells from CD123 Immunotherapy for Acute Myeloid Leukemia

Medicine, Hematology, Oncology, Life Sciences, Bioengineering, Immunology, Genetics,
epitope editing   CD123   immunotherapy   acute myeloid leukemia   hematopoietic stem cells   CAR-T  

Epitope Prime Editing Shields Hematopoietic Cells from CD123 Immunotherapy: A Novel Therapeutic Strategy for Acute Myeloid Leukemia Research Background and Problem Statement Acute Myeloid Leukemia (AML) is a malignant blood disease characterized by the abnormal differentiation of myeloid hematopoietic stem and progenitor cells (HSPCs). Its incidenc...

CRISPR dependency screens in primary hematopoietic stem cells identify KDM3B as a genotype-specific vulnerability in IDH2- and TET2-mutant cells

Medicine, Basic Medical Sciences, Oncology, Life Sciences, Biochemistry,
hematopoietic stem cells   KDM3B   epigenetics   clonal hematopoiesis   CRISPR screens   acute myeloid leukemia  

CRISPR-Dependent Screening in Primary Hematopoietic Stem Cells Identifies KDM3B as Specific Susceptibility for IDH2 and TET2 Mutant Genotypes Background and Significance Clonal Hematopoiesis (CH) refers to the abnormal growth of genetically distinct subclones of cells initiated by specific mutations in Hematopoietic Stem Cells (HSCs). This phenomen...

Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML

Medicine, Basic Medical Sciences, Hematology, Oncology, Life Sciences, Biochemistry,
orthogonal proteogenomic   acute myeloid leukemia   EVI1   PA2G4   druggable target   histone deacetylase inhibitors  

Orthogonal Proteogenomic Analysis Identifies Druggable PA2G4-MYC Axis in 3q26 AML Acute myeloid leukemia (AML) is a highly heterogeneous and aggressive malignancy. In particular, the 3q26 chromosomal abnormality subtype of AML has a complex pathogenic mechanism and lacks effective targeted therapies. To address this challenge, Matteo Marchesini and...